Literature DB >> 17576849

In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.

Olivier Grossi1, Jocelyne Caillon, Cedric Arvieux, Cedric Jacqueline, Denis Bugnon, Gilles Potel, Antoine Hamel.   

Abstract

We investigated the efficacies of moxifloxacin, cloxacillin, and vancomycin in a rabbit model of Staphylococcus aureus arthritis. No significant difference between therapeutic regimens was observed after a 7-day treatment. Oral moxifloxacin could be a suitable alternative to standard parenteral therapy for S. aureus arthritis.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17576849      PMCID： PMC2043244          DOI： 10.1128/AAC.01520-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

1.  A prospective 2-year study of 75 patients with adult-onset septic arthritis.

Authors:  M N Gupta; R D Sturrock; M Field
Journal:  Rheumatology (Oxford)       Date:  2001-01       Impact factor: 7.580

2.  Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections.

Authors:  Frédéric Frippiat; Françoise Meunier; Geneviève Derue
Journal:  J Antimicrob Chemother       Date:  2004-10-21       Impact factor: 5.790

3.  In vivo simulation of human pharmacokinetics in the rabbit.

Authors:  D Bugnon; G Potel; J Caillon; D Baron; H B Drugeon; P Feigel; M F Kergueris
Journal:  Bull Math Biol       Date:  1998-05       Impact factor: 1.758

4.  The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  J M Sierra; J G Cabeza; M Ruiz Chaler; T Montero; J Hernandez; J Mensa; M Llagostera; J Vila
Journal:  Clin Microbiol Infect       Date:  2005-09       Impact factor: 8.067

5.  Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.

Authors:  K Metzler; G M Hansen; Peter Hedlin; Elizabeth Harding; Karl Drlica; J M Blondeau
Journal:  Int J Antimicrob Agents       Date:  2004-08       Impact factor: 5.283

6.  Infection of rabbit knee joints after intra-articular injection of Staphylococcus aureus. Comparison with joints injected with Staphylococcus albus.

Authors:  A H Johnson; W G Campbell; B C Callahan
Journal:  Am J Pathol       Date:  1970-08       Impact factor: 4.307

7.  Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa.

Authors:  Y Q Xiong; G Potel; J Caillon; G Stephant; F Jehl; D Bugnon; P Le Conte; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

8.  Oral antimicrobial therapy for adults with osteomyelitis or septic arthritis.

Authors:  J Black; T L Hunt; P J Godley; E Matthew
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

9.  Concentrations of moxifloxacin in serum and synovial fluid, and ex vivo bactericidal activity against arthritis-causing pathogens.

Authors:  M Dan; O Keynan; Z Feldbrin; F Poch
Journal:  Diagn Microbiol Infect Dis       Date:  2004-04       Impact factor: 2.803

10.  Activity of and resistance to moxifloxacin in Staphylococcus aureus.

Authors:  Dilek Ince; Xiamei Zhang; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.